Abstract: Objective  Ontreatment markers such as skin toxicity was frequent and early phenomenon in antiepidermal growthfactor receptor (EGFR)monoclonal antibody (MoAb) treatment process for colorectal cancer patients,  However,  it is still unclear  if it is a considerable marker to make treatment decision. This study aimed to uncover this issue. Methods  Literature search for relevant studies was conducted on pubmed,  Embase and other databases from their inception through Oct,  2018. The metaanalysis was then performed with STATA 12.0. The hazard ratio(HR) was calculated with a 95%  condidence intrerval(CI).Results  The presences of skin toxicity in the ongoing antiEGFR treatment was associated with longer OS (HR=0.512，95%CI［0.443,0.58］，P<0.01)  and PFS (HR=0.587，95%CI［0.512, 0.662］，P<0.01).  On the other hand, the early clinical remission rate of KRAS mutation patients treated with EGFR MoAb was significantly higher than that of KRAS wild type patients (OR=3.029, 95%CI［2.474, 3.708］, P<0.01).Conclusion  Skin toxicity was one of prognostic factors in colorectal cancer patients. Given that skin toxicity appears to have little impact on quality of life, ontreatment markers could be potentially useful for treatment decision.

Key words: colorectal neoplasms; , receptor, , epidermal growth factor; , skin toxicity, curative effect